Literature DB >> 25271108

Interplay of drug metabolizing enzymes with cellular transporters.

Michaela Böhmdorfer1, Alexandra Maier-Salamon, Juliane Riha, Stefan Brenner, Martina Höferl, Walter Jäger.   

Abstract

Many endogenous and xenobiotic substances and their metabolites are substrates for drug metabolizing enzymes and cellular transporters. These proteins may not only contribute to bioavailability of molecules but also to uptake into organs and, consequently, to overall elimination. The coordinated action of uptake transporters, metabolizing enzymes, and efflux pumps, therefore, is a precondition for detoxification and elimination of drugs. As the understanding of the underlying mechanisms is important to predict alterations in drug disposal, adverse drug reactions and, finally, drug-drug interactions, this review illustrates the interplay between selected uptake/efflux transporters and phase I/II metabolizing enzymes.

Mesh:

Substances:

Year:  2014        PMID: 25271108     DOI: 10.1007/s10354-014-0301-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  74 in total

Review 1.  The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics.

Authors:  Yan Li; Jun Lu; James W Paxton
Journal:  Curr Drug Metab       Date:  2012-06-01       Impact factor: 3.731

Review 2.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

3.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Authors:  R W Robey; W Y Medina-Pérez; K Nishiyama; T Lahusen; K Miyake; T Litman; A M Senderowicz; D D Ross; S E Bates
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

4.  Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.

Authors:  T van Gelder; J Klupp; M J Barten; U Christians; R E Morris
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

5.  Metabolites and tissue distribution of resveratrol in the pig.

Authors:  María Azorín-Ortuño; María J Yáñez-Gascón; Fernando Vallejo; Francisco J Pallarés; Mar Larrosa; Ricardo Lucas; Juan C Morales; Francisco A Tomás-Barberán; María T García-Conesa; Juan C Espín
Journal:  Mol Nutr Food Res       Date:  2011-06-28       Impact factor: 5.914

6.  An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux.

Authors:  Etienne P A Neve; Per Artursson; Magnus Ingelman-Sundberg; Maria Karlgren
Journal:  Mol Pharm       Date:  2013-07-15       Impact factor: 4.939

7.  Erythromycin coadministration increases plasma atorvastatin concentrations.

Authors:  P H Siedlik; S C Olson; B B Yang; R H Stern
Journal:  J Clin Pharmacol       Date:  1999-05       Impact factor: 3.126

8.  Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver.

Authors:  C J Soroka; J M Lee; F Azzaroli; J L Boyer
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

Review 9.  Resveratrol: new avenues for a natural compound in neuroprotection.

Authors:  Mercè Pallàs; David Porquet; Alberto Vicente; Coral Sanfeliu
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Authors:  K S Lown; J C Kolars; K E Thummel; J L Barnett; K L Kunze; S A Wrighton; P B Watkins
Journal:  Drug Metab Dispos       Date:  1994 Nov-Dec       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.